41959-45-9

Usage

Uses

Since the specific applications or uses of 5-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE in industry or research are not widely documented, it is difficult to provide a detailed list of its uses. However, given its chemical structure and properties, it is likely that 5-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE could be used in the following ways:
Used in Pharmaceutical Industry:
5-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE could be used as an intermediate in the synthesis of various pharmaceutical compounds due to its reactive nature and the presence of the nitro group, which can be reduced or otherwise modified in chemical reactions.
Used in Chemical Research:
In the field of chemical research, 5-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE might serve as a starting material for the exploration of new chemical reactions or as a model compound to study the effects of the nitro group on the reactivity and properties of isoquinoline derivatives.
Used in Material Science:
5-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE's polarity and aromatic nature could make it a candidate for use in the development of new materials with specific electronic or optical properties, such as in organic electronics or as components of sensors.

InChI:InChI=1/C9H10N2O2/c12-11(13)9-3-1-2-7-6-10-5-4-8(7)9/h1-3,10H,4-6H2

Upstream product

• 607-32-9 5-nitroisoquinoline 
• 119-65-3 isoquinoline 

Downstream Products

• 123594-06-9 5-Nitro-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 201150-73-4 5-amino-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline 
• 1394241-47-4 C₁₆H₁₄N₂O₆S 
• 1350542-49-2 2,4-dinitro-5-(5-nitro-1,2,3,4-tetrahydroisoquinolin-2-yl)benzamide 
• 1350542-46-9 C₁₅H₁₂N₄O₆ 
• 1350542-48-1 3,5-dinitro-2-(5-nitro-1,2,3,4-tetrahydroisoquinolin-2-yl)benzoic acid 
• 1350542-47-0 2-[2,4-dinitro-6-(trifluoromethyl)phenyl]-5-nitro-1,2,3,4-tetrahydroisoquinoline 
• 123594-07-0 5-amino-3,4-dihydroisoquinoline-2(H)-carboxylic acid benzyl ester ester 

Relevant academic research and scientific papers

Synthesis of Carbamide Derivatives Bearing Tetrahydroisoquinoline Moieties and Biological Evaluation as Analgesia Drugs in Mice

Transient receptor potential vanilloid 1 (TRPV1) is a ligand-gated non-selective cation channel that is considered to be an important pain integrator. Tetrahydroisoquinoline, the prototypical antagonist of TRPV1, has a clear therapeutic potential. Here, a series of carbamide derivatives of tetrahydroisoquinoline were designed and synthesized. Preliminary biological tests suggested that the compounds I 1, I 2, and I 9 had favorable TRPV1 antagonism activity. In further studies, I 1 exhibited better antinociceptive activity than the positive control BCTC in diverse pain models. All of these results suggested that I 1 can be considered as the lead candidate for the further development of antinociceptive drugs. A novel carbamide derivative of tetrahydroisoquinoline I 1 had impressive TRPV1 antagonism activity (89.02%), exerting potency similarity with the positive control BCTC. Moreover, in mice, I 1 could significantly inhibit the reaction to pain and nociception in three different pain models, and trigger the analgesic activity in a dose-dependent manner.

AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

Tyrosine Kinase Inhibitor And Uses Thereof

Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

NOVEL NUCLEOSIDE TRANSPORT INHIBITORS

Compounds or compositions that are inhibitors and/or ligands of nucleoside transporters; and methods of treating cancer, heart disease and stroke, as well as AIDS and other infectious diseases

Synthesis and flow cytometric evaluation of novel 1,2,3,4-tetrahydroisoquinoline conformationally constrained analogues of nitrobenzylmercaptopurine riboside (NBMPR) designed for probing its conformation when bound to the es nucleoside transporter

Novel regioisomers of conformationally constrained analogues of the potent es nucleoside transporter ligand, nitrobenzylmercaptopurine riboside (NBMPR), designed for probing its bound (bioactive) conformation, were synthesized and evaluated as es transporter ligands by flow cytometry. Purine 6-position 5, 6, 7, or 8-nitro-1,2,3,4-tetrahydroisoquinolylpurine ribosides, in which the nitrobenzyl moiety in NBMPR has been locked into the nitro-1,2,3,4-tetrahydroisoquinoline system, were synthesized by reaction of the appropriate nitro-1,2,3,4-tetrahydroisoquinoline with 6-chloropurine riboside. Flow cytometry was performed using 5-(SAENTA)-X8-fluorescein as the competitive ligand. A high degree of variation in the es transporter binding capacity of the target compounds was observed, with the Ki values ranging from 0.45 nM for the most tightly bound compound (4) to 300 nM for the least tightly bound compound (5). The Ki of NBMPR was 0.70 nM, a little higher than that of compound 4. Compound 4 is the isomer that has the nitro group in the best orientation at the es transporter binding site compared to the other three compounds, 2, 3, and 5.